The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | The role of fedratinib in 2024 and beyond
Alexander Coltoff, MD, Medical University of South Carolina, Charleston, SC, discusses his talk on the role of fedratinib, the second JAK inhibitor approved in myelofibrosis (MF), in 2024 and beyond. Dr Coltoff suggests that the agent is sometimes forgotten about, despite its efficacy in ruxolitinib-resistant patients and in the frontline setting. Fedratinib inhibits BRD4 and is being studied in combination with other agents for the treatment of several hematological malignancies. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: Blueprint Medicines, CTI Biopharma.
